Hepatitis B drug developers chart slow progress forward, just like hep C before it. Read more here.

Hepatitis B Foundation invites providers and the public to participate in The Liver Meeting, Nov. 10-14, in Boston and online

A patient forum, co-moderated by Hepatitis B Foundation President Dr. Chari Cohen, will be held on Nov. 10. 

Doylestown, Pa., Oct. 13, 2023 – The Hepatitis B Foundation invites patient advocates, clinicians, and people living with hepatitis B, hepatitis D, or other liver disease, to participate in a special patient forum, online or in-person, Nov. 10 at The Liver Meeting.

Hepatitis B Foundation President Chari A. Cohen, DrPH, MPH, who will be co-moderating the patient forum, said, “The Hepatitis B Foundation thanks AASLD for fostering a space for people with liver disease to connect and share with clinicians; and we are pleased to provide the opportunity for hepatitis B and hepatitis D advocates to join these sessions and events as experts and partners.”

Sponsored by the American Association for the Study of Liver Diseases (AASLD), The Liver Meeting is an annual conference for clinicians, scientists and others engaged in work around liver diseases. It will be held this year Nov. 10-14 in Boston and online. Registration for patients, caregivers and patient advocates is $50.

Numerous Hepatitis B Foundation staff will be presenting at The Liver Meeting. If you are attending in person, or online, please join us at the following sessions (all times are EST):

  • Stronger Together (the patient forum): Patient-Provider Engagement in Liver Disease, Nov. 10, 8:30 a.m.
  • White House Hepatitis C Elimination Plan: What it Means for You and Your Community, Nov. 10, 4:30 p.m.
  • How to Amplify Advocacy to Achieve Viral Hepatitis Elimination, Nov. 12, 10:00 a.m.
  • New 2023 WHO Hepatitis B Global Guidelines in Diagnosis, Treatment and Service Delivery, Nov. 12, 3:30 p.m. 

The Hepatitis B Foundation also will be presenting multiple posters throughout the meeting – come find us at a poster session! 

About hepatitis B: The world’s most common serious liver infection, chronic hepatitis B, is caused by a virus that attacks and injures the liver. Each year up to 1 million people die from hepatitis B worldwide, even though it is preventable and treatable. Hepatitis B is a “silent epidemic” because most people do not have symptoms when they are newly or chronically infected. Thus, they can unknowingly infect others and continue the spread of hepatitis B. For people who are chronically infected but don’t have any symptoms, their livers are still being silently damaged, which can develop into serious liver disease such as cirrhosis or liver cancer.

About the Hepatitis B Foundation: As the world’s leading hepatitis B advocacy and research organization, the Hepatitis B Foundation is one of the most active proponents of improving hepatitis B screening, prevention, and treatment of the disease. We are the only nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. Founded in 1991, the Hepatitis B Foundation is based in Doylestown, Pa., with offices in Washington, D.C., and Philadelphia. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter, Instagram and Facebook (@hepbfoundation) or call us at 215-489-4900.